Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON PLC (ICLR) delivers essential clinical research services across 100+ countries, supporting pharmaceutical and biotechnology development through all trial phases. This news hub provides investors and industry professionals with timely updates on operational milestones, financial performance, and strategic initiatives shaping global drug development.
Access authoritative reporting on regulatory submissions, partnership announcements, and clinical trial advancements directly impacting ICON's market position. Our curated feed eliminates information fragmentation by centralizing earnings calls, governance updates, and technology implementations critical for evaluating contract research organizations.
Key coverage areas include phase III trial initiations, FDA/EMA regulatory interactions, acquisition strategies, and capacity expansion projects. Bookmark this page for real-time updates on ICON's patient recruitment innovations and quality control enhancements that maintain compliance with evolving global standards.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, announced that shareholders approved all resolutions at its Annual General Meeting held on July 22, 2025. The meeting saw strong participation with 59,889,939 total votes cast across various resolutions.
Key approvals included the re-election of all eight board members, with particularly strong support for Anne Whitaker (99.4% approval) and Dr. Steve Cutler (99% approval). Shareholders also ratified EY as auditors and approved measures regarding share allotment, pre-emption rights, and overseas market purchases.
ICON plc (NASDAQ: ICLR) reported its Q2 2025 financial results with mixed performance indicators. The company achieved gross business wins of $2.97 billion, up 10.6% from Q1 2025, and net business wins of $2.06 billion with a book-to-bill ratio of 1.02.
Q2 revenue reached $2.02 billion, representing a 0.8% increase from Q1 2025 but a 4.8% decrease year-over-year. Net income was $183.0 million ($2.30 per diluted share), up 30.7% from Q2 2024. The company's adjusted EBITDA was $396.0 million (19.6% of revenue).
ICON has expanded its share repurchase program by $500 million to a total of $1 billion and updated its full-year 2025 guidance, projecting revenue between $7.85-$8.15 billion and adjusted EPS of $13.00-$14.00.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, has been recognized as a top-performing CRO for phase 1 clinical trials according to an independent Industry Standard Research (ISR) report. The company achieved the highest overall sponsor satisfaction score of 7.4/10 among large CROs.
The comprehensive analysis, based on feedback from 159 industry professionals, revealed ICON's superior performance across 17 operational metrics, leading in 14 categories. The company demonstrated excellence in delivery metrics, staff characteristics, and accessibility metrics. Notably, ICON was the only large CRO to improve across all four brand strength metrics compared to 2024, marking its sixth consecutive year of outperforming weighted average scores in phase 1 trials.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, has received multiple prestigious awards in the first half of 2025. The company earned the AI Project of the Year Award for its enterprise-grade AI Assistant implementation, and was recognized on TIME Magazine's sustainability rankings, placing 57th out of 500 companies globally.
Notable achievements include being named Best CRO in APAC at the 2025 Asia Pacific Biopharma Excellence Awards and recognition as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards. Additionally, over 30 ICON employees received awards at the PharmaTimes International Clinical Researcher of the Year competition.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has announced that its CEO, Dr. Steve Cutler, will present at the William Blair 45th Annual Growth Stock Conference. The presentation is scheduled for Wednesday, June 4, 2025, at 10:40 AM CT. The company will provide updates and links to the live webcast, where available, on the Investor section of their website under the "Events" tab.
ICON (NASDAQ: ICLR) has released its ICON Cares 2024 Report, highlighting significant achievements in environmental, social, and governance (ESG) goals. The company received a 72/100 score from EcoVadis (silver medal) and a B- score on CDP Climate Change response. In 2024, ICON supported over 1,270 clinical studies involving more than 416,000 patients, contributing to 19 medicine approvals.
Notable environmental achievements include exceeding their near-term SBTi target with a 70.06% reduction in Scope 1 & 2 GHG emissions, achieving 84.67% renewable electricity consumption, and reducing laboratory kit wastage by 15-20%. The company expanded its AI and robotic process automation capabilities while strengthening governance protocols.
ICON plc (NASDAQ: ICLR) has released findings from a survey of 155 biotech and pharma professionals regarding multi-indication cardiometabolic R&D for obesity therapies. The survey reveals that 83% of sponsors are pursuing multi-indication approaches in obesity research, but many underestimate the complexity of these strategies.
Key findings show that 90% of respondents are not implementing non-traditional study arms like master protocols, while only 14% pursue multiple indications based on longitudinal data. Furthermore, only 19% follow patients for more than three years. Despite these challenges, 77% of respondents believe multi-indication R&D would lower healthcare costs.
In response, ICON has launched their new Centre for Obesity, featuring an infrastructure of 100 sites and a developing database of 10,000 pre-screened patients across obesity-related comorbidities to facilitate rapid multi-indication research.
ICON reported mixed Q1 2025 financial results with net business wins of $2,022 million and a book-to-bill ratio of 1.01. Revenue decreased 4.3% year-over-year to $2,001.3 million, while adjusted EBITDA was $390.7 million (19.5% of revenue).
Key highlights include:
- Closing backlog of $24.7 billion, up 6.0% from Q1 2024
- GAAP net income of $154.2 million ($1.90 per diluted share)
- Adjusted net income of $258.3 million ($3.19 per diluted share)
- Net debt of $2.9 billion with a net debt to adjusted EBITDA ratio of 1.7x
The company updated its 2025 guidance, now expecting revenue between $7,750-$8,150 million (representing -6.4% to -1.6% YoY) and adjusted EPS of $12.75-$14.25. Performance was impacted by market volatility, customer decision delays, and elevated cancellations. The company repurchased $250 million worth of stock at an average price of $184.
ICON plc (NASDAQ: ICLR) has scheduled its first quarter 2025 earnings release and conference call. The company will release its Q1 2025 financial results after market close on Wednesday, April 30, 2025. A conference call and webcast to discuss the results will be held the following day on Thursday, May 1, 2025 at 8:00am ET. A webcast replay will be available approximately one hour after the call concludes. Any updates or changes to these events will be posted on the Investor section of ICON's website under 'Events'.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
